Hydrocortisone, progesterone, testosterone, triiodothyronine, thyroxine, chorionic gonadotropin, prolactin, alpha-fetoprotein, luteinizing, follicle-stimulating, and thyrotropic hormones were measured in human sera and in Lyphochek Immunoassay Plus Control reference sera (Bio-Rad Laboratories, USA) using 4 commercial kits (Alkor Bio Inc. and Roche, automated analyzer Roche Cobas Core; DPC, automated analyzer Immulite; Bayer, automated analyzer ACS:180). Coordination and correlation between these kits was observed, the coordination decreasing in the series Alkor Bio/Bayer, Alkor Bio/Roche, and Alkor Bio/DPC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Association between Clot Waveform Analysis Parameters and the Severity of Liver Cirrhosis.
Thromb Haemost
January 2025
Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Clot waveform analysis (CWA) provides a global assessment of hemostasis and may be useful for patients with cirrhosis with complex hemostatic abnormalities. This study aimed to assess the association between prothrombin time (PT-) and activated partial thromboplastin time (aPTT-) based CWA parameters and cirrhosis severity and prospectively evaluate the role of CWA in predicting mortality and acute decompensation (AD) over 1 year.
Methods: This prospective study included adult patients with cirrhosis between June 2021 and December 2023 at Chulalongkorn University Hospital.
Background: The analytical performance characteristics for the plasma Glial Fibrillary Acidic Protein (GFAP) immunoassay currently under development on Beckman Coulter, Inc. Access2™ and DxI9000™ analyzers is described. Blood GFAP levels may be indicative of the extent of neurologic injury in diseases such as TBI and stroke and maybe used as a marker of disease progression in other diseases such as multiple sclerosis.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) plasma biomarkers related to amyloid (A), tau (T), and neurodegeneration (N) can potentially be used to identify these pathological features of the disease, as shown in recent studies. Our objective was to compare the clinical and analytical performance of plasma AD biomarkers measured using the single-molecule array (Simoa) and Lumipulse platforms.
Method: We quantified ATN and AT plasma biomarkers in 127 patients with mild cognitive impairment (MCI) (n = 81), AD (n = 30), and non-AD dementia (n = 16) using a Simoa HD-1/HD-X analyser (Quanterix) and a Lumipulse G600II automated platform (Fujirebio Europe NV).
Biomarkers.
Alzheimers Dement
December 2024
Department of Psychiatry, University of Magdeburg,, Magdeburg, Sachsen-Anhalt, Germany.
Background: To support diagnosis of Alzheimer's disease (AD), concentrations of Aβ, tTau and pTau(181) and the Aβ/Aβ ratio are determined in cerebrospinal fluid (CSF). To increase standardization and comparability between diagnostic laboratories, certified reference material (CRM) is used to evaluate the trueness of novel assays. Due to lack of CRMs for tTau, pTau(181), and Aβ, comparability may be assessed by comparing assays from different manufacturers.
View Article and Find Full Text PDFBackground: Hyperphosphorylated Tau is a pathologic hallmark of the neurofibrillary tangles in Alzheimer's Disease (AD). p-Tau is a promising blood-based biomarker in AD research, drug development, diagnosis, disease monitoring, and patient care. Several assays for p-Tau in plasma have been previously described, however there is a need to make this test easily available to the clinical laboratories around the world and more accessible to the patients and the clinicians.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!